Posted on 13/11/2009 in Pharmaceutical Company Financials Nycomed performed in a "satisfactory" manner during the third quarter of 2009, it has been stated.
This is according to the firm's chief executive officer Hakan Bjorklund, who made the comments upon the release of the company's financial results this week.
The figures show that Nycomed's total net turnover increased by 0.9 per cent during the period to 820 million euros (734 million pounds).
Additionally, sales of pantoprazole remained resilient during this timeframe and the organisation's breakthrough cancer pain drug Instanyl was approved in the EU.
Mr Bjorklund stated: "Furthermore, the positive phase III trial results were published in the medical journal The Lancet and presented at the European Respiratory Society meeting in Vienna."
In September, Nycomed announced plans to invest up to 75 million euros (68 million pounds) into a brand new cutting-edge pharmaceutical production plant in Russia.
Other news stories from 13/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
